Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680390 | 0.77 | CRBN (0.47) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL30184407 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL5515897 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL24379329 | 0.77 | CRBN (0.47) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL17552856 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL24411108 | 0.77 | CRBN (0.47) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL17169674 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL17865988 | 0.74 | PARP1 (0.40) | ALDH1A1TSHROPRM1TDP1 | |
| SCHEMBL12041950 | 0.74 | CRBN (0.44) | CRBNDDB1ALDH1A1TSHRCHRM2 | |
| SCHEMBL23979399 | 0.72 | CRBN (0.42) | CRBNDDB1ALDH1A1TSHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, MAT2A | CRBN 3099/4885DDB1 1996/4885ALDH1A1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.